SCHEMBL5204924

SCHEMBL5204924

NC(=CC(=O)C(Cc1ccccc1)N(Cc1ccccc1)Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
HPGD P15428 1/20 0.38
ALPI P09923 1/20 0.38
PKM P14618 1/20 0.38
PTGS1 P23219 1/20 0.38
XIAP P98170 1/20 0.38
SLC7A5 Q01650 1/20 0.38
CYP1A2 P05177 1/20 0.37
CTSD P07339 1/20 0.36
CES1 P23141 2/20 0.36
CES2 O00748 1/20 0.36
AKR1B1 P15121 1/20 0.36
SRR Q9GZT4 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
CPA1 P15085 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2059512 1.00 EPHX1 (0.39) EPHX1HPGDALPIPKMPTGS1
SCHEMBL11913036 1.00 EPHX1 (0.39) EPHX1HPGDALPIPKMPTGS1
SCHEMBL8947146 1.00 EPHX1 (0.39) EPHX1HPGDALPIPKMPTGS1
SCHEMBL14600170 1.00 EPHX1 (0.39) EPHX1HPGDALPIPKMPTGS1
SCHEMBL2059511 1.00 EPHX1 (0.39) EPHX1HPGDALPIPKMPTGS1
SCHEMBL13541094 0.93 L3MBTL1 (0.41) EPHX1HPGDALDH1A1
SCHEMBL2438636 0.89 ALOX5 (0.51) PTGS1
SCHEMBL2438637 0.89 ALOX5 (0.51) PTGS1
SCHEMBL2434733 0.86 DPP4 (0.40)
SCHEMBL2440000 0.86 DPP4 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0724563-B1 Intermediates for the preparation of a substituted 2,5-diamino-3-hydroxyhexane. ABBOTT LAB (US) 1999-09-01 EP claimed
EP-0724563-A1 PROCESS FOR THE PREPARATION OF A SUBSTITUTED 2,5-DIAMINO-3-HYDROXYHEXANE ABBOTT LABORATORIES (US) 1996-08-07 EP claimed
US-5491253-A Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane ABBOTT LABORATORIES (US) 1996-02-13 US claimed
WO-1995011224-A1 PROCESS FOR THE PREPARATION OF A SUBSTITUTED 2,5-DIAMINO-3-HYDROXYHEXANE ABBOTT LABORATORIES (US) 1995-04-27 WO claimed
CN-111393329-A Preparation method of ritonavir and lopinavir intermediate 安徽一帆香料有限公司 2020-07-10 CN disclosed
EP-1313712-B1 PROCESS AND INTERMEDIATES FOR PREPARING RETROVIRAL PROTEASE INHIBITORS ABBOTT LAB (US) 2007-05-09 EP disclosed
US-6667404-B2 Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent ABBOTT LABORATORIES 2003-12-23 US disclosed
US-20030195362-A1 Retroviral protease inhibiting compounds KEMPF DALE J (US) 2003-10-16 US disclosed
EP-1313712-A2 PROCESS AND INTERMEDIATES FOR PREPARING RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 2003-05-28 EP disclosed
EP-0916646-B1 Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane ABBOTT LAB (US) 2003-05-02 EP disclosed
EP-1302468-A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 2003-04-16 EP disclosed
US-6531610-B1 Intermediate acylating carbonate ABBOTT LABORATORIES 2003-03-11 US disclosed
US-5491253-A Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane ABBOTT LABORATORIES (US) 1996-02-13 US disclosed
US-5484801-A Pharmaceutical composition for inhibiting HIV protease ABBOTT LABORATORIES (US) 1996-01-16 US disclosed
EP-0674513-A4 1995-10-25 EP disclosed
EP-0674513-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1995-10-04 EP disclosed
WO-1995020384-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1995-08-03 WO disclosed
WO-1995009614-A1 PHARMACEUTICAL COMPOSITION ABBOTT LABORATORIES (US) 1995-04-13 WO disclosed
WO-1995007696-A1 PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1995-03-23 WO disclosed
WO-1994014436-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195362-A1 Retroviral protease inhibiting compounds PREP, SERPINB1, PRSS1 EPHX1 2132/4885HPGD 3006/4885ALPI 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.